Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancr… (NCT01875198) | Clinical Trial Compass
TerminatedNot Applicable
Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
Stopped: because of difficulties of enrolling appropriate participants
South Korea1 participantsStarted 2013-04
Plain-language summary
When distal pancreatectomy is carried out for left-sided pancreatic cancer, splenectomy is usually performed not only for margin-negative resection but also for effective clearance of the splenic hilar lymph nodes. However, there was no scientific evidence regarding the justifiability for spleen resection. Considering potential immunological function of the spleen, the investigators hypothesized that distal pancreatectomy without pancreatectomy for left-sided pancreatic cancer is superior than Distal pancreatectomy with pancreatectomy in terms of short-term perioperative outcomes and disease-specific overall survival.
Who can participate
Age range20 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Ductal adenocarcinoma
✓. Age ≥20 and ≤80
✓. General performance status: the Karnofsky score\> 70% or ECOG 0-1
✓. Potentially Curative resection
✓. Tumor size \< 3cm
✓. Pancreatic cancer located on neck or body portion
✓. No invasion to spleen or spleen hilum
✓. No combined resection except Lt. adrenal gland
Exclusion criteria
✕. Unresectable or locally advanced, metastatic case
✕. Patients who do not want surgery
✕. ASA (American society of anesthesiologists' physical status classification) score: ≥3
✕. Patients who not want to involve the clinical trial
✕. Patients who are unable to read or understand the informed consent, sign a consent form (eg, mental retardation, blindness, illiteracy, foreign, etc.)